

Science in Translation Consultancy

Stefan Kostense, PhD

Scientific Operations Accelerator for Drug Development

s.kostense@scienceintranslation.com

[LinkedIn profile](#)



Executive Summary

PhD-trained immunologist and biopharmaceutical R&D leader with 25 years of experience across biotech, pharma, and CRO organizations. Expertise spans translational strategy, biomarker development, bioanalysis, assay validation, and clinical development support from discovery through proof-of-concept. I help organizations accelerate development programs, strengthen scientific decision-making, and build high-performing teams that deliver critical milestones.


Value proposition

“Biomarkers double clinical success rates”

For biotech in early drug discovery this means faster decisions, less risk, higher NPV and stronger investors confidence.

I help you:

- **Identify** high-impact biomarkers early
- **Validate** assays and endpoints for regulatory success
- **Integrate** translational data to attract partners/funding



In the early stages of preclinical development, a robust translational strategy ensures that opportunities for biomarker discovery and co-development are identified early, enabling data-driven decision making throughout the program. By integrating translational science from the outset, development risks can be identified and mitigated before they lead to costly delays or program termination.

A clear biomarker and translational roadmap also strengthens the scientific rationale of a program, helping companies communicate value to investors and strategic partners.

As programs progress into clinical development, I help teams implement and operationalize their translational strategy through biomarker-driven decision making, assay development, and data integration. This approach supports patient selection, demonstrates target engagement and mechanism of action, informs dose selection, and generates the evidence needed to make critical development decisions. Ultimately, a well-executed translational strategy increases the probability of clinical success and accelerates the path toward regulatory approval.

Selected Career Highlights

- Progressed several vaccine and antibody programs from preclinical to clinical development
- Executed pharmacodynamic and biomarker bioanalysis for 20+ clinical trials
- Discovered biomarker panels for early detection of lung cancer and Alzheimer's disease, and discovered predictive biomarkers for treatment of type 1 diabetes.
- Implemented genetic and antibody based diagnostic tests in a population based screening study

Science in Translation

Translating science from lab to clinic. Translating vision into results.

Helping biotech and pharmaceutical organizations move promising therapies from discovery to clinical proof-of-concept by integrating translational science, biomarker strategy, and operational execution.